Gene testing and reporting for Ovarian cancer specimens
NHS Greater Glasgow and Clyde requires an end-to-end diagnostic service for FFPE block processing, DNA based Homologous Repair Deficiency (HRD) and BRCA1 and BRCA2 gene testing and reporting for Ovarian cancer specimens. The technical processing and laboratory reporting must be validated to ISO 15189 (2022) standards or equivalent and the underlying technology used must be clinically validated with demonstrable assessment against clinical outcomes. The service must have a robust trackability process to ensure that FFPE blocks are processed sensitively and returned to Laboratory Genetics NHS GGC. This service is required for approximately 200 tests per annum and the service must be available by 1st December 2026. The provider must be able to meet NHS GGC boards Information Technology and Security and Information Governance frameworks by completion of Data Protection Impact Assessment (DPIA), and establishing a Data Processing Agreement (DPA) along with a Systems Security Policy (SSP) as applicable. All information governance, cyber-security and any contractual agreements must be established and in place by 01/12/2026 as the current HRD service, based within the UK, will cease to exist from 01/12/2026. The supplier must be able to provide a fixed cost per test, between 01/12/2026-31/12/2027. There are no Scottish Genomic Laboratories able to provide this test. We require a rapid solution to ensure that patients needing the HRD test can access the test and associated treatment pathways based on the test result. Not having a test available for this patient cohort will lead to significant patient harm and even early death.